Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD grew its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 7.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,283,421 shares of the company's stock after purchasing an additional 629,315 shares during the period. Price T Rowe Associates Inc. MD owned about 9.92% of Scholar Rock worth $401,231,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of SRRK. GAMMA Investing LLC lifted its stake in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after purchasing an additional 269 shares during the period. Global Retirement Partners LLC increased its stake in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after acquiring an additional 766 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after buying an additional 1,031 shares during the last quarter. Amalgamated Bank raised its holdings in Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after buying an additional 620 shares during the period. Finally, KBC Group NV bought a new stake in Scholar Rock in the fourth quarter worth about $131,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $42.67.

Insider Buying and Selling

In other Scholar Rock news, CFO Edward H. Myles sold 142,292 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $35.62, for a total value of $5,068,441.04. Following the completion of the transaction, the chief financial officer now owns 111,345 shares in the company, valued at $3,966,108.90. The trade was a 56.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, General Counsel Junlin Ho sold 5,742 shares of Scholar Rock stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total value of $211,477.86. Following the completion of the transaction, the general counsel now owns 189,295 shares of the company's stock, valued at $6,971,734.85. The trade was a 2.94 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 250,231 shares of company stock worth $9,056,086. Insiders own 13.30% of the company's stock.

Scholar Rock Price Performance

SRRK stock traded down $1.57 during midday trading on Friday, reaching $32.81. The stock had a trading volume of 694,304 shares, compared to its average volume of 1,243,667. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The company's fifty day simple moving average is $32.77 and its 200 day simple moving average is $35.72. The company has a market cap of $3.11 billion, a price-to-earnings ratio of -13.96 and a beta of 0.56.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.